- Home
- AEON vs QNCX Comparison
AEON vs QNCX Comparison
Compare AEON & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEON
- QNCX
- Stock Information
- Founded
- AEON N/A
- QNCX 2012
- Country
- AEON United States
- QNCX United States
- Employees
- AEON N/A
- QNCX N/A
- Industry
- AEON Biotechnology: Pharmaceutical Preparations
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AEON Health Care
- QNCX Health Care
- Exchange
- AEON Nasdaq
- QNCX Nasdaq
- Market Cap
- AEON 36.4M
- QNCX 34.4M
- IPO Year
- AEON N/A
- QNCX 2019
- Fundamental
- Price
- AEON $0.61
- QNCX $1.78
- Analyst Decision
- AEON Strong Buy
- QNCX Strong Buy
- Analyst Count
- AEON 1
- QNCX 3
- Target Price
- AEON $5.00
- QNCX $9.67
- AVG Volume (30 Days)
- AEON 106.3K
- QNCX 1.4M
- Earning Date
- AEON 11-13-2024
- QNCX 11-13-2024
- Dividend Yield
- AEON N/A
- QNCX N/A
- EPS Growth
- AEON N/A
- QNCX N/A
- EPS
- AEON N/A
- QNCX N/A
- Revenue
- AEON N/A
- QNCX N/A
- Revenue This Year
- AEON N/A
- QNCX N/A
- Revenue Next Year
- AEON N/A
- QNCX N/A
- P/E Ratio
- AEON N/A
- QNCX N/A
- Revenue Growth
- AEON N/A
- QNCX N/A
- 52 Week Low
- AEON $0.60
- QNCX $0.51
- 52 Week High
- AEON $17.17
- QNCX $2.14
- Technical
- Relative Strength Index (RSI)
- AEON 28.55
- QNCX 67.44
- Support Level
- AEON $0.60
- QNCX $1.56
- Resistance Level
- AEON $0.88
- QNCX $1.76
- Average True Range (ATR)
- AEON 0.07
- QNCX 0.26
- MACD
- AEON -0.03
- QNCX 0.03
- Stochastic Oscillator
- AEON 2.62
- QNCX 67.54
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing innovative precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics.